Background: Esophageal squamous cell carcinoma (ESCC) is often diagnosed at an advanced and incurable stage. Information on driver genes and prognosticators in ESCC remains incomplete. The objective was to elucidate significantly mutated genes (SMGs), mutational signatures, and prognosticators in ESCC.
Introduction
Esophageal cancer ranks the seventh most commonly diagnosed cancer type and the sixth leading cause for cancer-related death worldwide with a 5-year survival rate as low as 13% [1] . The incidence and mortality rates of esophageal cancer are higher in China (4th in ranking) with esophageal squamous cell carcinoma (ESCC) accounting for 90% of esophageal cancer [2] . The wellestablished risk factors for developing ESCC include alcohol consumption and tobacco smoking [3] . Single-nucleotide polymorphisms in ALDH2 (rs671, AG/AA) and ADH1B (rs1229984, GG) were reported to associate with increase the risk of ESCC [4] .
Recent next-generation sequencing studies have advanced our understanding of genetic alterations in ESCC [5] [6] [7] [8] [9] [10] [11] . Genes involved in cell cycle, RTK/PI3K/AKT circuit, chromatin remodeling, and the Notch signaling pathway are frequently altered [7] . TP53 is the most significantly mutated genes (SMGs) in ESCC with mutation frequency reaching 93% [7] . The EP300 mutation was reported to be independent prognostic factor for ESCC [7, 10] . TENM3 is a member of teneurin encoding gene family and its genomic variations have been observed in human cancers [12, 13] .
The characteristic mutational signatures are the fingerprints of endogenous and exogenous factors that have acted over the course of tumorigenesis. For example, substitution of C>T at TpCpW (where W ¼ A or T) is associated with over-activity of APOBEC RNA-editing enzyme [14] . In ESCC, the APOBEC mutational activity is significantly greater in ZNF750 mutated cancer samples as compared with those without ZNF750 mutations [15] . Prevalent C>T mutations at CpG dinucleotide via spontaneous deamination of 5-methylcytosine is associated with aging; a risk factor for cancer development.
The purposes of this study were to identify new SMGs and genetic prognosticators for patients diagnosed with ESCC, and to characterize the mutational signatures in ESCC by jointly interrogating genomic data and clinical information from published ESCC studies [5] [6] [7] [8] [9] [10] [11] .
Materials and methods

Genomic data and clinical information
All somatic mutations were initially extracted from seven previous studies comprising 549 ESCC cases. Five of these seven studies have survival data. Detailed information is shown in supplementary Table S1 , available at Annals of Oncology online. Clinical information is provided in supplementary Table S2 , available at Annals of Oncology online. Detailed descriptions are provided in supplementary material, available at Annals of Oncology online. The genotypes of ALDH2 at rs671 and ADH1B at rs1229984 were derived from samples with bam files available. All previously called mutations were re-annotated after filtering through an in-house reference genomics database composed of a panel of 1600 healthy Chinese individuals. Previously called mutations were discarded if they present in >2 alignment bam files in the reference database.
Identification of SMGs
We used four algorithms, namely MutSigCV [16] , MutSigCL [17] , MutSigFN [17] and '20/20þ' ratio-metric [18] to identify SMGs, and applied stringent filtering criteria to eliminate false positives. We required that mutations of these genes were not only statistically significant by MutSig algorithm but also detected in 4 independent studies out of the seven studies included in our meta-analysis. In addition, we required that these genes were shown to be expressed in human cancer cell lines [19] and the TCGA pan-cancer dataset [20] . We also compared the mRNA expression levels of these genes in another ESCC study that only has microarray-based gene expression profiling [21] . Detailed procedures are provided in supplementary material, available at Annals of Oncology online.
Deciphering mutational signature operative in the genome
We applied the framework proposed by Kim et al. [22] to extract mutational signatures. This framework is based on Bayesian variant nonnegative matrix factorization and it can automatically determine the optimal number of mutational signatures. We also used nonnegative least approach to deconvolute the mutational portrait of ESCC against mutational signatures 1, 2, 13 and 16, which resemble signatures extracted from ESCC and was curated by the Catalogue of Somatic Mutations in Cancer (COSMIC). These COSMIC signatures were obtained from http://cancer.sanger.ac.uk/cosmic/signatures (5 September 2017, date last accessed). Detailed procedures are provided in supplementary material, available at Annals of Oncology online.
Prognostic analysis of mutated genes
Kaplan-Meier survival analysis and Cox proportional hazards model were employed to analyze the association between mutated genes and prognosis. Confounding factors that were not significant in the univariate Cox model were not included in the multivariate Cox analysis except for age and gender. Kaplan-Meier survival and Cox regression analyses were carried out with the R survival package (2.40-1). P-value < 0.05 was considered to be statistically significant. The drug treatment information for these ESCC was not available.
Results
SMGs in ESCC
A total of 67 592 coding somatic mutations were obtained from 7 previously published studies totaling 549 ESCC cases (a median of 107 mutations per tumor). We used MutSigCV [16] , MutSigCL [17] , MutSigFN [17] and '20/20þ' ratio-metric [18] to re-annotate SMGs that met the criteria of being positively accumulated, clustered at a hotspot and of functional importance. In total, we identified 26 SMGs (Figure 1 ), including 18 previously reported ESCC driver genes (e.g. TP53, KMT2D and NOTCH1) and 8 novel SMGs (i.e. NAV3, TENM3, PTCH1, TGFBR2, RIPK4, PBRM1, USP8 and BAP1). According to the '20/20þ' ratio-metric, three newly identified SMGs, namely PTCH1, PRM1 and BAP1, were categorized as tumor suppressor genes. The mutation plots of these eight novel SMGs are shown in supplementary Figure S1 , available at Annals of Oncology online. The mRNA expression level of these 26 SMGs in tumor tissues versus matched adjacent normal control tissue were examined in a separate microarray-based ESCC gene expression dataset [21] . The analyses showed that 19 SMGs were significantly upregulated or downregulated (supplementary Figure S2 , available at Annals of Oncology online; Paired t-test, q < 0.1). NAV3, mutated in 6.9% of ESCC cases, was reported to be recurrently mutated in five cancer types from a previous pan-cancer study [20] ; however, NAV3 function in carcinogenesis has not been well established. TENM3 was mutated in 4% of ESCC. Eleven of the 12 non-silent mutations in TENM3 were missense mutations. The ubiquitin specific protease 8 encoding gene USP8, identified as an oncogene in Cushing's disease [23, 24] , was found to harbor hotspot mutations at p.N764K (n ¼ 3) and p.R763W (n ¼ 2) in ESCC. Mutations of PTCH1 did not reach statistical significance in our previous ESCC study, albeit, it was suggested as a key gene implicated in ESCC [15] . RIPK4, encoding for receptor-interacting protein kinase 4, was reported to be involved in head and neck squamous cell carcinoma [25] . TGFBR2 is a major player of TGF-beta signaling pathway and its alteration has been linked to multiple human cancer types [20] . PBRM1 and BAP1 are both involved in chromatin remodeling and are frequently mutated in multiple human cancer types including renal carcinoma, HNSC, pancreatic, bladder and lung cancers [26] .
To gain insights into the genetic alterations in canonical signaling pathways, we curated cancer-related signaling pathways from previous studies [20, 27, 28] and applied PathScan [29] to evaluate the mutational significance of these pathways. Our result showed that chromatin modification, DNA damage response, RAS signaling, cell cycle, genomic integrity maintenance and Notch signaling were significantly enriched for somatic mutations (Supplementary Table S3 , available at Annals of Oncology online). Association of their mutation status with survival outcomes is provided in Supplementary Table S4, available at Annals of Oncology online.
Mutational signatures operative in ESCC
The overall mutational pattern of ESCC was dominated by C>T and C>G mutations (Figure 2A ). We extracted three mutational signatures (i.e. signatures 1, 2 and 16; Figure 2B ) from ESCC with varying mutational activities, which are defined by the number of mutations generated by each corresponding mutational signature ( Figure 2C ). These three signatures were named according to the COSMIC signature nomenclature. The clocklike signature 1, featured by C>T transitions at CpG dinucleotides, is thought to be connected with age-related accumulation of spontaneous deamination of 5-methylcytosine. Signature 2, characterized by C>T mutations at TpCpW (where W ¼ A or T) trinucleotide sequences, is thought to result from over-activity of the APOBEC RNA-editing enzyme [14] . Signatures 1 and 2 are widespread among many human cancer types including ESCC [15] . Signature 16, contributed to 16.5% of the total mutation load and characterized by T>C at the trinucleotide, ApTpW (where W ¼ A, G or T). To rule out the possibility that signature 16 may result from random noise, we deconvoluted somatic mutation data against four COSMIC Signatures (i.e. Signatures 1, 2, 13 and 16; see supplementary material, available at Annals of Oncology online) that closely resemble these three signatures extracted from ESCC, and we observed that signature 16 was indeed present in ESCC (supplementary Figure S3 , available at Annals of Oncology online).
Mutational signatures correlated with clinical features
To identify mutagenic factors that are responsible for signature 16, we carried out logistic regression analysis for mutational activity of signature 16 versus alcohol consumption and risk genotypes of ALDH2 and ADH1B. Our analysis showed that increased mutational activity of signature 16 was significantly linked to alcohol consumption and the presence of the ALDH2 rs671 AG/AA polymorphism ( Figure 3A ). This association remained significant when tobacco smoking was taken into account ( Figure 3B ). We also carried out mutational signature analysis for HNSC and liver cancer, and found that signature 16 was present in these two cancer types (supplementary Figures S4 and S5 , available at Annals of Oncology online, respectively). This association between alcohol consumption and signature 16 was also observed in HNSC (supplementary Figure S6 , available at Annals of Oncology online).
The association between alcohol consumption and signature 16 in liver cancer was not assessed due to the missing alcohol assumption information in the TCGA liver cancer dataset. In addition, unsupervised hierarchical clustering for activities of mutational signatures identified two distinctive clusters; C1/2 (supplementary Figure S7A , available at Annals of Oncology online), and their association with survival outcome was statistically significant (supplementary Figure S7B and C, available at Annals of Oncology online).
SMG mutation associated with alcohol exposure
We analyzed the association between SMGs and alcohol consumption and found eight SMGs enriched in the alcohol consumption group (Fisher's exact test, P < 0.05; supplementary Figure S8A , available at Annals of Oncology online). We further examined the difference of mutational activity of signature 16 with respect to the mutational status of these eight SMGs. We observed that increased mutational activity of signature 16 was associated with mutations in ZNF750 (median: 26.3 versus 14.0; P ¼ 0.002), TP53 (median: 15.3 versus 11.6; P ¼ 0.02) and EP300 (median: 23.3 versus 14.1; P ¼ 0.01; supplementary Figure S8B , available at Annals of Oncology online). The association between TP53 mutation status and alcohol consumption signature (i.e. signature 16) was manifested by a significantly higher T>C mutation fraction of TP53 in the alcohol group versus nonalcohol group (22.2% versus 12.4%; one-sided proportion test, P ¼ 0.006). A previous study investigating the impact of acetaldehyde (the first metabolite of alcohol) on TP53 mutations showed that acetaldehyde treatment induced T>C mutations in TP53 [30] . In HNSC, mutations in TP53 were also significantly associated with increased mutational activity of signature 16 (median: 18.3 versus 8.05; one-sided Wilcoxon test, P < 0.001). In liver cancer, this association was marginally significant (median: 33.4 versus 32.9; one-sided Wilcoxon test, P ¼ 0.07).
Prognostic markers for ESCC
We carried out Kaplan-Meier survival analysis in each of the individual ESCC studies for the 26 identified SMGs and found that mutated TENM3 was significantly associated with the survival outcomes in 4 out of the 5 collected ESCC datasets that included survival data (supplementary Table S5 , available at Annals of Oncology online; log-rank test, P < 0.05). Mutation of EP300 was significantly associated with poor survival (supplementary Figure S9 , available at Annals of Oncology online). When examining the association between gene mutation and survival in the combined ESCC cohort of 549 cases, we found that mutation of TENM3 was the most significant association after controlling for multiple hypothesis tests ( Figure 4A ; log-rank test, adjusted P < 0.001). Moreover, mutated TENM3 remained statistically significant after taking into account age, gender, TNM staging, tumor grade and mutation of EP300 ( Figure 4B ). To rule out the confounding impact of geographical area, we took the geographical area as strata variable in multivariate Cox model and found that mutation of TENM3 was still significant (HR: 5.78; 95% CI: 2.78-12.05; P < 0.001). We next examined TENM3 expression and found that TENM3 was significantly overexpressed in tumor tissue versus matched normal control tissue (supplementary Figure S10A , available at Annals of Oncology online; median: 9.68 versus 7.78; Wilcoxon test, P < 0.001). ESCC patients with abnormally high expression of TENM3 (See supplementary material, available at Annals of Oncology online) were associated with poor prognosis (supplementary Figure S10B and C, available at Annals of Oncology online).
TP53 was the most significantly mutated driver gene in the combined ESCC dataset (86.7%). In this study, we analyzed the association of TP53 hotspot mutations (n 5) and survival outcome. The result showed that TP53 p.R213* mutation (n ¼ 12) was significantly associated with poor prognosis (Figure 4C and D) . TP53 p.R213* mutation was still statistically significant (HR: 3.86; 95% CI: 1.78-8.37; P < 0.001) with geographical area taken as strata variable in a multivariate Cox model. TP53 p.R213* and TENM3 mutations remained statistically significant when they were included as confounding variables in a multivariate Cox model (supplementary Figure S11 , available at Annals of Oncology online).
Discussion
In this study, we carried out a meta-analysis of 549 ESCC cases from 7 published studies and identified several less frequently mutated SMGs that were not recognized previously. We revealed a mutational signature and SMGs that are associated with alcohol consumption. We further identified mutations of TENM3 and TP53 (p.R213*) as poor prognosticators for ESCC. In addition, the existence of an alcohol consumption signature (i.e. signature 16) was also present in two recent ESCC studies [31, 32] .
A major advantage for this meta-analysis is the inclusion of a large sample size for ESCC. The statistical power to detect SMGs mutated in 3% of samples is only 43%; therefore, a large sample size of ESCC samples is critical for the detection of low mutation frequency SMGs [17] . On the other hand, a potential problem is the batch effect introduced by different cohorts. To overcome this weakness, an SMG was required to be mutated in at least four independent ESCC datasets. In addition, to increase the robustness of our analysis, we used four algorithms to re-annotate mutations and identified 18 previously reported and, more importantly, eight novel SMGs. The novel SMGs include NAV3, TENM3, RIPK4, PBRM4 and USP8. Recurrent mutations of NAV3 have been reported in several cancer types [20] but not in ESCC. TENM3 was both non-silently mutated and overexpressed in tumor tissues compared to adjacent normal control tissue, suggesting TENM3 may function as an oncogene in ESCC. TENM3 was also observed Figure 3 . The association between mutational activity of signature 16 and alcohol consumption with genotypes of ALDH2 and ADH1B (A), and tobacco smoking (B) taken into account. The confounding factors were shown on left-side of each forest plot, and the corresponding estimated odds ratio and P-value were shown on the middle and right-side panels, respectively.
to be frequently mutated in many other human cancer types (supplementary Table S6 , available at Annals of Oncology online) obtained from cBioPortal [33] . The TENM3 gene encodes a protein that belongs to the teneurin family. Teneurins are highly conserved transmembrane glycoprotein receptors that have been implicated in tumor development and drug resistance [12] . Genomic aberration of TENM3 was reported in neuroblastoma, and its dysregulation was associated with survival outcomes [13] . In our analysis, mutation of TENM3 was associated with deceased survival outcomes in four datasets and ranked as the most statistically significant prognostic factor in the combined ESCC dataset. Mutations at a hotspot of TP53, p.R213*, was also shown to be an independent prognostic factor.
Another key finding from our study is identification of the alcohol consumption associated signature 16, which was not extracted from our previous study [15] likely due to limited sample size and the relatively smaller mutational activity of signature 16 in comparison with Signatures 1 and 2. In the meta-analysis, signature 16 consisted of 16.5% of total mutations in ESCC ( Figure 2C ).
The association of signature 16 with alcohol consumption in ESCC contributed to 7.1% of total mutations in HNSC (supplementary Figure S12 , available at Annals of Oncology online). This finding bridges the gap between alcohol consumption and somatic mutations in relation to ESCC tumorigenesis. The mechanisms through which alcohol and/or its metabolites (e.g. acetaldehyde) induce distinct mutations in ESCC are still elusive and require future investigation. It has been suggested that alcohol consumption might induce TP53 mutations in breast cancer [34] , non-small-cell lung cancer [35] and rectal tumors [36] ; probably due to accumulation of oxidative stress resulting from alcohol metabolism. Future studies will be needed to illustrate whether alcohol consumption causes TP53 mutations as a critical mechanism for ESCC development.
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